

COOPER & DUNHAM LLP

ATTORNEYS AT LAW

1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036

TELEPHONE: (212) 278-0400

CHRISTOPHER G. DUNHAM
NORMAN H. ZIVIN
JOHN P. WHITE
WILLIAM E. PELTON
ROBERT D. KATZ
DONNA A. TOBIN
RICHARD S. MILNER
RICHARD F. JAWORSKI
PAUL TENG
GARY J. GERSHIK
JASON S. MARIN
MARIA V. MARUCCI
ARIAN A. BARYALAI
ASHTON J. DELAUNEY
CINDY YANG
BRIAN J. AMOS
JOSEPH B. GROSS
DANIEL N. SMITH*

IVAN S. KAVRUKOV
PETER D. MURRAY
JAY H. MAION
ROBERT B. G. HOROWITZ
PETER J. PHILLIPS
WENDY E. MILLER
ROBERT T. MALDONADO
ERIC D. KIRSCH
ALAN J. MORRISON
PEDRO C. FERNANDEZ
KEITH J. BARKAUS
ANTHONY V. FLINT
AUDE GERSPACHER
JEFFREY C. SHIEH
NARESH SRITHARAN
DAVID J. KCRWICK*
TONIA A. SAYOUR

FACSIMILE: (212) 391-0525
(212) 391-0526
(212) 391-0630

OF COUNSEL
DONALD S. DOWDEN

SCIENTIFIC ADVISOR
MURIEL M. LIBERTO, PH.D.

FOUNDED 1887
www.cooperdunham.com

FACSIMILE TRANSMISSION

* NEW YORK STATE BAR ADMISSION PENDING

PLEASE DELIVER THE FOLLOWING PAGES

TO : Examiner T. McKenzieCOMPANY/FIRM : U.S. Patent and Trademark OfficeFACSIMILE NO.: (571) 273-0670FROM : Gary J. Gershik/NDPTOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 43DATE : October 7, 2004 TIME:

IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (212) 278-0400.

MESSAGE: COMMUNICATION IN RESPONSE TO OCTOBER 4, 2004 TELEPHONE CONFERENCE WITH EXAMINER AND SECOND AMENDMENT UNDER 37 C.F.R. §1.312, in connection with Timothy Norris et al. STABLE POLYMORPH ON N-(3-ETHYNYLPHENYL)-6, 7-BIS (2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF, Serial No. 09/711,272, filed November 9, 2000.

=====

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY BE AN ATTORNEY-CLIENT COMMUNICATION CONTAINING INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Docket No. 1919/62814-A/JPW/GJG/NDP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Timothy Norris et al.
Serial No. : 09/711,272 Group Art. Unit: 1624
Filed : November 9, 2000 Examiner: T. McKenzie
For : STABLE POLYMORPH OF N-(3-ETHYNYLPHENYL)-6,
7-BIS (2-METHOXYETHOXY)-4-QUINAZOLINAMINE
HYDROCHLORIDE, METHODS OF PRODUCTION, AND
PHARMACEUTICAL USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
October 7, 2004


SIR:

FACSIMILE CERTIFICATE OF TRANSMISSION
IN CONNECTION WITH THE ABOVE-IDENTIFIED APPLICATION

Date of Facsimile: October 7, 2004. I hereby certify that this paper is being transmitted to the Assistant Commissioner for Patents on the date indicated above by facsimile and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Printed Name: SWALKIRIA BEWITZ

Respectfully submitted,


John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel (212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Timothy Norris et al.

Serial No. : 09/711,272

GROUP ART UNIT: 1624

Filed : November 9, 2000

EXAMINER: T. McKenzie

For : STABLE POLYMORPH ON N-(3-ETHYNYLPHENYL)-6, 7-BIS
(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE,
METHODS OF PRODUCTION, AND PHARMACEUTICAL USES
THEREOF

1185 Avenue of the Americas
New York, New York 10036
October 7, 2004

BY FACSIMILE 571-273-0670

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

Sir:

COMMUNICATION IN RESPONSE TO OCTOBER 4, 2004 TELEPHONE
CONFERENCE WITH EXAMINER AND SECOND AMENDMENT UNDER
37 C.F.R. §1.312

This Communication confirms an October 4, 2004 telephone conference during which Examiner McKenzie informed the undersigned that the Second Supplemental Amendment filed on December 15, 2003 has been entered in the above-identified application.

In addition, Examiner McKenzie sought authorization to cancel the terms "autoimmune" and "atherosclerosis" from claim 74 and the term "atherosclerosis" from claim 92. In response, Applicants are filing this Second Amendment under 37 C.F.R. §1.312 amending the claims as requested by the Examiner and also providing a clean copy of the amended claims as Exhibit A.

A Notice of Allowance was issued May 26, 2004 in connection with the above-identified application; a Communication under 37 C.F.R. §1.312 was filed July 22, 2004; an Amendment under

Applicant: Timothy Norris et al.
Serial No.: 09/711,272
Filed: November 9, 2000
Page 2 of 22

37 C.F.R. §1.312 was filed August 18, 2004; and the issue fee was paid on August 25, 2004. Applicants are awaiting the Examiner to return the initialed Form PTO-1449 to Applicants as requested in their July 22, 2004 Communication.

Applicants hereby request that the following amendment to the claims be entered in the subject application. A clean copy of the claims as amended is attached hereto as **Exhibit A** for the Examiner's convenience.